Literature DB >> 19210904

Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy.

Lawrence DuBuske1, Krzysztof Kowal.   

Abstract

Allergic rhinitis (AR) is associated with histamine-mediated physiologic events. The currently used histamine antagonists are all inverse agonists that bind and inactivate histamine H1 receptors. Second-generation antihistamines are much more H1-receptor selective with less central nervous system penetration than first-generation agents. Antihistamines typically are more effective in seasonal than perennial AR and do not demonstrate significant relief of nasal congestion. The recent availability of some second-generation antihistamines as over-the-counter products clearly places them as the preferred first-line treatment for mild to moderate AR based on safety when compared with first-generation over-the-counter antihistamines. The remaining prescription-only second-generation antihistamines, fexofenadine, desloratadine, and levocetirizine, all have unique attributes. Antihistamines in oral, intranasal, or intraocular formulations will likely remain among the mainstays of allergy therapeutics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19210904     DOI: 10.1007/s11882-009-0021-6

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  56 in total

Review 1.  The role of histamine in allergic disease: re-appraisal of its inflammatory potential.

Authors:  C Bachert
Journal:  Allergy       Date:  2002-04       Impact factor: 13.146

2.  Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis.

Authors:  G A Rossi; M A Tosca; G Passalacqua; B Bianchi; C Le Grazie; G W Canonica
Journal:  Allergy       Date:  2005-03       Impact factor: 13.146

3.  Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile.

Authors:  N Cranswick; J Turzíkova; M Fuchs; R Hulhoven
Journal:  Int J Clin Pharmacol Ther       Date:  2005-04       Impact factor: 1.366

4.  Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis.

Authors:  G Walter Canonica; Jean Bousquet; Geneviève Van Hammée; Claus Bachert; Stephen R Durham; Ludger Klimek; Joaquim Mullol; Paul B Van Cauwenberge
Journal:  Respir Med       Date:  2006-05-24       Impact factor: 3.415

5.  Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine.

Authors:  M Ciebiada; M Gorska Ciebiada; T Kmiecik; L M DuBuske; P Gorski
Journal:  J Investig Allergol Clin Immunol       Date:  2008       Impact factor: 4.333

6.  The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis.

Authors:  J Ngamphaiboon; C Direkwattanachai; N Visitsunthorn; M Vangveeravong; M Tiensuwan
Journal:  Asian Pac J Allergy Immunol       Date:  2005-12       Impact factor: 2.310

7.  Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders.

Authors:  B M Prenner; D Capano; A G Harris
Journal:  Clin Ther       Date:  2000-06       Impact factor: 3.393

8.  Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis.

Authors:  Jonathan Corren; William Storms; Jonathan Bernstein; William Berger; Anjuli Nayak; Harry Sacks
Journal:  Clin Ther       Date:  2005-05       Impact factor: 3.393

9.  Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis.

Authors:  Frank C Hampel; Barbara Kittner; Julius H van Bavel
Journal:  Ann Allergy Asthma Immunol       Date:  2007-12       Impact factor: 6.347

10.  Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber.

Authors:  Piyush Patel; Carrie D'Andrea; Harry J Sacks
Journal:  Am J Rhinol       Date:  2007 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.